Warning letter
Amman Pharmaceutical Industries: warning letter of Feb 14, 2024
FDA warning letter 668867 · Center for Drug Evaluation and Research | CDER
Key facts
| Reference number | 668867 |
|---|---|
| Company | Amman Pharmaceutical Industries |
| Subject | CGMP/Finished Pharmaceuticals/Adulterated |
| Issue date | Feb 14, 2024 |
| Posted date | Feb 27, 2024 |
| Issuing office | Center for Drug Evaluation and Research | CDER |
| Product type | Drugs |
| CFR sections cited | 211.194(a), 211.42(c)(10), 211.113(b), 211.34, 211.22(a) |
| Inspection city | Amman |
| Inspection start date | Aug 7, 2023 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: